AF-CARD Registry (Real-World Clinical Practice Registry of Patients With Atrial Fibrillation) (NCT07437456) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
AF-CARD Registry (Real-World Clinical Practice Registry of Patients With Atrial Fibrillation)
Russia3,500 participantsStarted 2026-09
Plain-language summary
Multicenter Non-Interventional Real-World Clinical Practice Registry of Patients with Atrial Fibrillation. The primary objective of the registry is an epidemiological assessment of the characteristics, clinical outcomes, and therapeutic approaches in patients with atrial fibrillation and a CHA₂DS₂-VASc score of no more than 2 for men and no more than 3 for women.
Who can participate
Age range
18 Years – 64 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Retrospective Part The retrospective part will include patients who attended a physician consultation for atrial fibrillation three years ago and who met the inclusion criteria at that time.
Inclusion criteria for the retrospective part:
* Male or female patients aged 18 to 64 years at the time of data registration;
* Presence of a specialist-confirmed diagnosis of atrial fibrillation;
* CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women.
Non-inclusion criteria for the retrospective part:
* Age under 18 years;
* Age over 64 years;
* CHA₂DS₂-VASc score greater than 2 for men and greater than 3 for women;
* Inability to undergo screening examination and follow-up;
* Organ or tissue transplantation less than 5 years prior to study enrollment;
* Open heart surgery (coronary artery bypass grafting, valve replacement, reconstructive aortic surgery) within 6 months prior to study enrollment;
* Established diagnosis of dementia of any severity and/or established diagnosis of moderate or severe encephalopathy, as well as other conditions precluding independent regular medication intake.
Prospective Part
Inclusion criteria for the prospective part:
* Male or female patients aged 18 to 64 years at the time of data registration;
* Presence of a specialist-confirmed diagnosis of atrial fibrillation;
* CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women at the time of screening.
Non-inclusion criteria for the prospective part:
* Age under…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Cumulative incidence of thromboembolic complications